Myocardial remodelling: pharmacological targets

Bibliography

• COHN JN: Structural basis for heart failure. ventricular remodeling and its pharmacological inhibition. Circulation (1995) 91:2504–2507.
   PubMed Web of Science ®Google Scholar
• SWYNGHEDAUW B: Molecular mechanisms of myocardial remodeling. Physiol Rev (1999) 79:215–262.
   PubMed Web of Science ®Google Scholar
• ••The last review on cardiac remodelling. Thenew concept is based on the latest research on molecular biology of the heart.
   Google Scholar
• TREVATHAN WR, SMITH EO, MCKENNA JJ (Eds): Evolutionary Medicine. Oxford University Press, New York, USA (1999).
   Google Scholar
• •A major book which provides the basis of a new understanding of medicine.
   Google Scholar
• SCHREIBER SS, ROTHSCHILD MA, EVANS C, REFF F, ORATZ M: The effect of pressure or flow stress on right ventricular protein synthesis in the face of constant and restricted coronary perfusion. Clin. Invest (1975) 55:1–11.
   Google Scholar
• •A seminal paper from one the founders of molecular cardiology. The paper showed for the first time the very early activation of protein synthesis after mechanical overload.
   Google Scholar
• SCHIAFFINO S, SAMUEL JL, SASSOON D et al: Nonsynchronous accumulation of alpha-skeletal actin and beta-myosin heavy chain mRNAs during early stages of pressure-overload- induced cardiac hypertrophy demonstrated by in situ hybridization. Circ. Res. (1989) 64:937–948.
   PubMed Web of Science ®Google Scholar
• •A nicely illustrated paper based on in situ hybridation, showing the early reprogramming of the overloaded cells.
   Google Scholar
• DELCAYRE C, KLUG D, THIEM NV, MOUAS C, SWYNGHEDAUW B: Aortic perfusion pressure as early determinant of beta-isomyosin expression perfused hearts. Am..1. Physiol (1992) 263:H1537–H1545.
   PubMed Web of Science ®Google Scholar
• GIBBS CL, CHAPMAN JB: Cardiac mechanics and energetics: chemomechanical transduction in cardiac muscle. Jim. I Physic] (1985) 249:H199–H206.
   Web of Science ®Google Scholar
• ••A seminal work on cardiac energymetabolism.
   Google Scholar
• SONNENBLICK EH: Force velocity relations in mammalian heart muscle. Am. Physic] (1962) 205:931–939.
   Google Scholar
• ••The first paper that really showed that thedepression of V is a major event in the course of mechanical overload.
   Google Scholar
• ALPERT NR, MULIERI LA: Increased myothermal economy of isometric force generation in compensated cardiac hypertrophy induced by pulmonary artery constriction in the rabbit - a characterization of heat liberation on normal and hypertrophied right ventricular papillary muscles. Circ. Res (1982) 50:491–500.
   PubMed Web of Science ®Google Scholar
• ••A major paper that was the first to evidencethe adaptational process in cardiac overload in terms of thermodynamic.
   Google Scholar
• SWYNGHEDAUW B, WANSTOCK F, COURTAULT D: Les effets du dinitrophenol sur l'hypertrophie cardiaque expérimentale du rat. Pathol Biol. (Paris)(1968) 16:667–669.
   Google Scholar
• MERCADIER JJ, SAMUEL JJ, MICHEL JB et al.: Atrial natriuretic factor gene expression in rat ventricle during experimental hypertension in rat ventricle during experimental hypertension. Am. I Physiol (1989) 257:H979–H987.
   PubMed Web of Science ®Google Scholar
• LOMPRE AM, SCHWARTZ K, d'ALBIS A, LACOMBE G, THIEM NV, SWYNGHEDAUW B: Myosin isozymes redistribution in chronic heart overloading. Nature (1979) 282:105–107.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration of qualitativechanges in genetic expression during mechanical overloading of the heart.
   Google Scholar
• CHARLEMAGNE D, ORLOWSKI J, OLIVIERO P et al.: Alteration of (Na+, K±)-ATPase subunit mRNA and protein levels in hypertrophied heart. I Biol. Chem. (1994) 269:1541–1547.
   Web of Science ®Google Scholar
• ••The first demonstration of an isoenzyme shift occurring on this crucial enzyme during mechanical overloading.
   Google Scholar
• TAEGTMEYER H, OVERTURF ML: Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension (1988) 11:416–426.
   PubMed Web of Science ®Google Scholar
• CHEVALIER B, HEUDES D, HEYMES C et al.: Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR. Circulation (1995) 92:1947–1953.
   PubMed Web of Science ®Google Scholar
• LOMPRE AM, LAMBERT F, LAKATTA EG, SCHWARTZ K: Expression of sarcoplasmic reticulum Ca2+-ATPase and calsequestrine genes in rat heart during ontogenic development and aging. Circ. Res. (1991) 69:1380–1388.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrates the diminution of this enzyme during cardiac overload.
   Google Scholar
• TAKIMOTO K, LI D, HERSHMAN KM, JACKSON EK, LEVITAN ES: Decreased expression of Kv4.2 and novel Kv4.3 K+ channel subunit mRNAs in ventricles of renovascular hypertensive rats. Circ. Res. (1997) 81:533–539.
   Google Scholar
• HWANG DM, DEMPSEY AA, LEE CY, LIEW CC: Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags. Cenomics (2000) 66:1–14.
   Google Scholar
• ••The first group to use genome-basedtechnology in cardiac research.
   Google Scholar
• STANTON LW, GARRARD LJ, DAMM D et al.: Altered gene patterns of gene expression in response to myocardial infarction. Circ. Res (2000) 86:939–945.
   PubMed Web of Science ®Google Scholar
• SEHL PD, TAI JTN, HILLAN KJ et al.: Application of the cDNA microarrays in determining molecular phenotype in cardiac growth, development and response to injury. Circulation (2000) 101:1990–1999.
   PubMed Web of Science ®Google Scholar
• GULCH RW: The effects of elevated chronic loading on the action potential of mammalian myocardium. Ma Cell. Cardiol. (1980) 12:415–420.
   PubMed Web of Science ®Google Scholar
• •The first demonstration of the augmentation of the repolarisation time during chronic mechanical overloading.
   Google Scholar
• GWATHMEY JK, COPELAS L, MACKINNON R et al.: Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ. Res (1987) 61:70–76.
   PubMed Web of Science ®Google Scholar
• BESSE S, ROBERT V, ASSAYAG P, DELCAYRE C, SWYNGHEDAUW B: Non-synchronous changes in myocardial collagen mRNA and protein during aging. Effect of DOCA-salt hypertension. Am." Physiol. (1994) 267:H2237–H2244.
   Web of Science ®Google Scholar
• LEVY BI, TEDGUI A (Eds) Biology of the arterial wall. Kluwer Acad. Pub., Boston, USA (1999).
   Google Scholar
• LAKATTA E: Cardiovascular regulatory mechanisms in advanced age. Physiol Rev (1993) 73:413–467.
   PubMed Web of Science ®Google Scholar
• •An important full review on the biology of the senescent heart.
   Google Scholar
• SHIMIZU M, UMEDA K, SUGIHARA N et al.: Collagen remodeling in myocardia of patients with diabetes. Clin. Pathoi (1993) 46:32–36.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND CGG, FISHER BM, FRIER BM, DARGIE HJ, MORE IA, LINDOP GB: Endomyocardial biopsy pathology in insulin-dependent diabetic patients with abnormal ventricular function. Histopathology (1989) 14:593–602.
   PubMed Web of Science ®Google Scholar
• VENTURA HO, MESSERLI FH, DUNN FG, FROHLICH ED: Left ventricular hypertrophy in obesity: discrepancy between echo and electrocardiogram. Am. Coll Cardiol (1983) 1:682–703.
   Web of Science ®Google Scholar
• ASSAYAG P, CHARLEMAGNE D, MARTY I et al.: Effects of low-flow ischemia on myocardial function and calcium-regulating proteins in adult and senescent rat hearts. Cardiovasc. Res (1998) 38:169–180.
   PubMed Web of Science ®Google Scholar
• •The first demonstration of an ischaemic-induced activation of genetic expression.
   Google Scholar
• WANG GL, JIANG BH, RUE EA, SEMENZA GL: Hypwda-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular 02 tension. Proc. Nati Acad. Sci. USA (1995) 92:5510–5514.
   PubMed Web of Science ®Google Scholar
• MARSH JD: Coregulation of calcium channels and beta-adrenergic receptors in cultured chick embryo ventricular cells. Clin. Invest. (1989) 84:817–823.
   Google Scholar
• MEGGS LG, COUPET J, HUANG H et al.: Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction. Circ. Res. (1993) 72:1149–1162.
   PubMed Web of Science ®Google Scholar
• REGITZ-ZAGROSEK V, FRIEDEL, N, HEYMANN A et al.: Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation (1995) 91:1461–1471.
   PubMed Web of Science ®Google Scholar
• •The first paper to show the down-regulation of All receptors during end-stage heart failure in human.
   Google Scholar
• BING OHL, BROOKS WW, ROBINSON KG et al.: The Spontaneously Hypertensive Rat as a model of the transition from compensated left ventricular hypertrophy to failure. Ma Cell Cardiol. (1995) 27:383–396.
   PubMed Web of Science ®Google Scholar
• •The description of one of the best experimental model for studying the transition to heart failure.
   Google Scholar
• INOKO M, KIHARA Y, MORII I, FUJIWARA H, SASAYAMA S: Transition from compensatory hypertrophy to dilated failing left ventricles in Dahl salt-sensitive rats. Am.j Physiol (1994) 267:H2471–H282.
   Web of Science ®Google Scholar
• PFEFFER MA, BRAUNWALD E: Ventricular remodeling after myocardial infarction. Circulation (1990) 81:1161–1172.
   PubMed Web of Science ®Google Scholar
• ••The description of the most popularexperimental model of myocardial infarction.
   Google Scholar
• SWYNGHEDAUW B, CHARLEMAGNE D: What is wrong with positive inotropic drugs : lessons from basic science and clinical trials. Ear: Heart J. (2002) In press.
   Google Scholar
• THE DIGITALIS INVESTIGATION GROUP: The effect of digoxin on mortality and morbidity in patients with heart failure. N Eng]. J. Med. (1997) 336:525–533.
   PubMed Web of Science ®Google Scholar
• ••The first trial specifically targeted todigitalis.
   Google Scholar
• DELLITALIA LJ, MENG QC, BALCELLS E et al.: Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. I Clin. Invest. (1997) 100:253–258.
   PubMed Web of Science ®Google Scholar
• URATA H, HEALY B, STEWART RW, BUMPUS FM, HUSAIN A: Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. (1990) 66:883–890.
   PubMed Web of Science ®Google Scholar
• •The first paper to demonstrate alternative pathways for All formation.
   Google Scholar
• WEBER KT (Ed): Wound Healing in Cardiovascular Disease. Futura Publ., Armonk New York, USA (1995).
   Google Scholar
• •A fundamental book on myocardial fibrosis, written by one of the pioneers in this field.
   Google Scholar
• BROWN NJ, VAUGHAN DE: Angiotensin-converting inhibitors. Circulation (1998) 97:1411–1420.
   PubMed Web of Science ®Google Scholar
• CHEVALIER B, MANSIER P, CALLENS F, SWYNGHEDAUW B: The beta-adrenergic system is modified in compensatory pressure cardiac overload in rats: physiological and biochemical evidence. J. Cardiovasc. Pharmacol. (1989) 13:412–420.
   PubMed Web of Science ®Google Scholar
• CAMPBELL DJ, AGGARWAL A, ESLER M, KAYE D: Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet (2001) 358:1609–1610.
   PubMed Web of Science ®Google Scholar
• •A major paper that showed that n-blockers are also able to lower plasma All.
   Google Scholar
• COHN JN, TOGNONI G for the VALSARTAN HEART FAILURE TRIAL INVESTIGATORS: A randomized trial of the angiotensin-receptor blocker Vasartan in chronic heart failure. N Eng]. J. Med. (2001) 345:1667–1675.
   PubMed Web of Science ®Google Scholar
• SABRI A, LEVY BI, POITEVIN P et al.: Differential roles of AT1 and AT2 receptor subtypes in vascular trophic and phenotypic changes in response to stimulation with angiotensin II. Arterioscler: Thromb. Biol. (1997) 17:257–264.
   Google Scholar
• •A major paper that showed that ATI blockers were able to create fibrosis in experimental models.
   Google Scholar
• ICHIHARA S, SENBOMATSU T, PRICE EJr, ICHIKI T, GAFFNEY FA, INAGAMI T: Angiotensin II Type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation (2001) 104:346–351.
   PubMed Web of Science ®Google Scholar
• SENBONMATSU T, ICHIHARA S, PRICE E Jr, GAFFNEY FA, INAGANI T: Evidence for angiotensin II Type 2 receptor-mediated cardiac myocyte enlargment during in vivo pressure overload. " Clin. Invest. (2000) 106:R25–R29.
   PubMed Web of Science ®Google Scholar
• AKISHITA M, IWAI M, WU L et al.: Inhibitory effect of angiotensin II Type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation (2000) 102: 1684-1689.
   Google Scholar
• BRODDE O-E: Beta 1-and beta2- adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol. Rev (1991) 43:203–241.
   PubMed Web of Science ®Google Scholar
• •A major review on the adrenergic system in the myocardium.
   Google Scholar
• MANSIER P, CHEVALIER B, BARNETT DB, SWYNGHEDAUW B: Beta 1-adrenergicand muscarinic receptor densities in compensatory cardiac hypertrophy of the adult rat. Pflügers Arch. Eui: I Physiol. (1993) 424:354–360.
   Google Scholar
• ANDERSON KM, ECKHART AD, WILLETTE RN, KOCH WJ: The myocardial beta-adrenergic system in Spontaneously Hypertensive Heart Failure (SHHF) rats. Hypertension (1999) 33[part 111:402–407.
   Google Scholar
• BRISTOW MR, GINSBURG R, UMANS V eta].: Betal- and beta2-adrenergic-receptor subpopulations in non failing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective betal receptor down-regulation in heart failure. Circ Res. (1986) 59:297–309.
   Google Scholar
• ••The first paper to show the down-regulationof the beta adrenergic receptors in HF in human.
   Google Scholar
• ESCHENHAGEN T, MENDE U, NOSE M et al: Increased messenger RNA level of the inhibitory G protein a subunit G1aiph._2 in human end-stage heart failure. Circ. Res (1992) 70:688–696.
   Google Scholar
• •The first demonstration of a diminution of Gia2 in HE
   Google Scholar
• McAREAVEY D, EXNER DV, LEIGH CURTIN E, DOMANSKI MJ: Beta-blockers in heart failure: recently completed and ongoing clinical trials. Expert Opin. Investig. Drugs (2000) 9(2):415–428.
   PubMed Web of Science ®Google Scholar
• FISHBEIN MC, LEI LQ, RUBIN SA: Long-term propranolol administration alters myocyte and ventricular geometry in rat hearts with and without infarction. Circulation (1988) 78:369–375.
   PubMed Web of Science ®Google Scholar
• PACKER M, CARVER JR, RODEHEFFER RJ et al.: Effects of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl. J. Med. (1991) 325:1468–1475.
   PubMed Web of Science ®Google Scholar
• IACCARINO G, KOCH WJ: Therapeutic potential of G-protein coupled receptor kinases in the heart. Expert Opin. Investig. Drugs (1999) 8(5):545–554.
   PubMedGoogle Scholar
• PITT B, REMME WJ, CODY R et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl. J. Med. (1999) 341:709–717.
   PubMed Web of Science ®Google Scholar
• •The first trial that evidences an effect of a diuretic on mortality and morbidity.
   Google Scholar
• DELCAYRE C, SILVESTRE JS: Aldosterone and the heart: towards a physiological function? Cardiovasc. Res. (1999) 43:7–12.
   Google Scholar
• SILVESTRE J-S, ROBERT V, HEYMES C et al.: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation.j Biol. Chem. (1998) 273:4883–4891.
   Web of Science ®Google Scholar
• ••The first demonstration of a myocardialsecretion of aldosterone.
   Google Scholar
• SILVESTRE JS, HEYMES C, OUBENAISSA A et al: Activation of cardiac aldosterone production in rat myocardial infarction. Circulation (1999) 99:2694–2701.
   PubMed Web of Science ®Google Scholar
• TRIPPODO NC, ROBL JA, ASAAD MM et al: Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin converting enzyme BMS-182657 in experimental hypertension and heart failure. J. Pharmacol. Exper. Ther: (1995) 275:745–752.
   Google Scholar
• GONZALEZ W, BESLOT F, LABOULANDINE I et al.: Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction. Pharmacol. Exper: Ther. (1996) 278:573–581.
   Google Scholar
• KNOWLES JW, ESPOSITO G, MAO L et al.: Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice." Clin. Invest. (2001) 197:975–984.
   Google Scholar
• •One of the first paper to show the antihypertrophic effects of ANP.
   Google Scholar
• KISHIMOTO I, ROSSI K, GARBERS DL: A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc. Natl. Acad. Sci. USA (2001) 98:2703–2706.
   PubMed Web of Science ®Google Scholar
• BRUTSAERT DL, MEULEMANS AL, SIPIDO KR, SYS SU: Effects of damaging endocardial surface on the mechanical performance of isolated cardiac muscle. Circ. Res. (1988) 62:358–366.
   PubMed Web of Science ®Google Scholar
• ••A pioneer work that evidences an endothelium-dependent regulation of cardiac contractility.
   Google Scholar
• PAULUS WJ, SHAH AM: NO and cardiac diastolic function. Cardiovasc. Res. (1999) 43:595–606.
   PubMed Web of Science ®Google Scholar
• •A major review on the myocardial effects of NO from one of the pioneer in the field.
   Google Scholar
• NAVA E, NOLL G, LOSCHER TF: Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation (1995) 91:2310–2313.
   PubMed Web of Science ®Google Scholar
• HEYMES C, VANDERHEYDEN M, BRONZWAER JGF et al.: Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation (1999) 99:3009–3016.
   PubMed Web of Science ®Google Scholar
• KAYE DM, WIVIOTT SD, BALLIGAND J-L, SIMMONS WW, SMITH TW, KELLY RA: Frequency-dependent activation of a constitutives nitric oxide synthase and regulation of contractile function in adult rat ventricular myocytes. Circ. Res. (1996) 78:217–224.
   PubMed Web of Science ®Google Scholar
• FERRARI R, BACHETTI T, CONFORTINI R et al: Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation (1995) 92:1479–1486.
   PubMed Web of Science ®Google Scholar
• •One of the first to demonstrate an elevation of TNF-a in HE
   Google Scholar
• FELDMAN AM, COMBES A, WAGNER D et al.: The role of Tumor Necrosis Factor in the pathophysiology of heart failure. Am. Coll. Cardiol (2000) 35:537–544.
   PubMed Web of Science ®Google Scholar
• FRANCIS GS: TNF-alpha and heart failure. Circulation (1999) 99:3213–3214.
   PubMed Web of Science ®Google Scholar
• MEIER P, FINCH A, EVAN G: Apoptosis in development. Nature (2000) 407:796–801.
   PubMed Web of Science ®Google Scholar
• DESWAL A, BOZKURT B, SETA Y et al: Safety and efficacy of a soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in patients with advanced heart failure. Circulation (1999) 99:3224–3226.
   PubMed Web of Science ®Google Scholar
• •The first report that concerns safety and efficacy of anticytokine therapy.
   Google Scholar
• JONES CG, CLELAND JGF: Meeting report - the LIDO, HOPE, MOXCON, and WASH studies. Eur. J. Heart Fail. (1999) 1:425–431.
   Google Scholar
• RAPPAPORT L, SAMUEL JL: Growth factors and the extracellular matrix. In: Growth Factors and the Cardiovascular System, Cummins P (Ed). Kluwers Acad. Pub., Boston, USA (1993):31–43.
   Google Scholar
• BRILLA CG, PICK R, TAN LB, JANICKIS, WEBER KT: Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. (1990) 67:1355–1364.
   PubMed Web of Science ®Google Scholar
• DIEZ J, LAVIADES C, MAYOR G, GIL MJ, MONREAL I: Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation (1995) 91:1450–1456.
   PubMed Web of Science ®Google Scholar
• •The first paper showing that the plasma concentration of procollagen peptides reflect the myocardial concentration of collagen.
   Google Scholar
• THARAUX PL, CHATZIANTONIOU C, FAKHOURI F, DUSSAULE JC: Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension (2000) 36:330–336.
   PubMed Web of Science ®Google Scholar
• CREEMERS EEJM, CLEUTJENS JPM, SMITS JFM, DAEMEN MJAP: Matrix Metalloproteinase inhibition after myocardial infarction. A new approach to prevent heart failure. Circ. Res. (2001) 89:201–210.
   Google Scholar
• ••A major review on this new therapeuticapproach.
   Google Scholar
• LEE RT: Matrix Metalloproteinase inhibition and the prevention of heart failure. Trends Cardiovasc. Med. (2001) 11:202–205.
   PubMed Web of Science ®Google Scholar
• SPINALE FG, COKER ML, KROMBACH SR et al.: Matrix Metalloproteinase inhibition during the development of congestive heart failure. Effects on left ventricular dimensions and function. Circ. Res. (1999) 85:364–376.
   Google Scholar
• HAUNSTETTER A, IZUMO S: Apoptosis. Basic mechanisms and implications for cardiovascular disease. Circ. Res. (1998) 82:1111–1129.
   Google Scholar
• TEIGER E, DAM TV, RICHARD L et al: Apoptosis in pressure-overload-induced heart hypertrophy in the rat. Gin. Invest. (1996) 97:2891–2897.
   PubMed Web of Science ®Google Scholar
• •A major paper that evidences stretch-induced apoptosis in mechanical overload.
   Google Scholar
• LI Z, BING OH, LONG X, ROBINSON KG, LAKATTA EG: Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am. J. Physiol (1997) 272:H2313–2319.
   PubMed Web of Science ®Google Scholar
• NARULA J, HAIDER N, VIRMANI R etal.: Apoptosis in myocytes in end-stage heart failure. N. Engl. J. Med. (1996) 335:1182–1189.
   Google Scholar
• OLIVETTI G, ABBI R, QUAINI F et al.: Apoptosis in the failing heart. N Engl Med. (1997) 336:1131–1141.
   PubMed Web of Science ®Google Scholar
• SCHUNKERT H, RIEGGER GAJ (Eds): Apoptosis M Cardiac Biology Kluwer Acad. Pub., Boston, USA (2000):352 pp.
   Google Scholar
• •A major book on the cardiovascular aspects of apoptosis.
   Google Scholar
• HAMET P, RICHARD L, DAM TV et al.: Apoptosis in target organs of hypertension. Hypertension (1995) 26:642–648.
   PubMed Web of Science ®Google Scholar
• KIM YM, BOMBECK CA, BILLIAR TR: Nitric oxide as a bifunctional regulator of apoptosis. Circ. Res (1999) 84:253–256.
   PubMed Web of Science ®Google Scholar
• NICHOLSON DW: From bench to clinic with apoptosis-based therapeutic agents. Nature (2000) 407:810–816.
   PubMed Web of Science ®Google Scholar
• ••A recent review on the state-of-the-artconcerning anti-apoptotic therapy.
   Google Scholar
• YUE TL, OHLSTEIN EH, RUFFOLO RR: Apoptosis: a potential target for discovering novel therapies for cardiovascular diseases. Curr. Op. Chem. Biol. (1999) 3:474–480.
   PubMed Web of Science ®Google Scholar
• MOCANU MM, BAXTER GE YELLON DM: Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br. Pharmacol (2000) 130:197–200.
   PubMed Web of Science ®Google Scholar
• LEE D, LONG SA, ADAMS JL et al: Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. I. Biol. Chem. (2000) 275:16007–16024.
   Web of Science ®Google Scholar